

Thursday, April 15, 2021
4:00 to 5:00 pm
Zoom

Attendees: Wadih Arap, Elisa Bandera, Adam Berger, Willetta Boswell, Chang Chan, Shridar Ganesan, Carolyn Heckman, Christian Hinrichs, Howard Hochster, Anita Kinney, Edmund Lattime, Gina Londino-Greenberg, Rita Musanti, Renata Pasqualini, Sharon Pine, Hatem Sabaawy, Sarah Scharf, Zhiyuan Shen, Ioannis Stasinopoulos, Linda Tanzer, Eileen White, X. F. Steven Zheng

Agenda

1. Development of a patient-derived xenograft service for translational research at CINJ (Sabaawy)
 - Please see presentation.
 - PDX models could be a bridge between pre-clinical and clinical research.
 - This type of service could also be a supportive resource for large multi-PI/multi-project grants.
 - o It was noted that there has been a push to have such resources available for these types of research funding opportunities.
 - A module is available to integrate PDX work with EPIC.
 - Priority tumor types for this service would be dependent on available resources and would start with those with the highest potential for success.
 - o Glioblastoma, prostate cancer, and breast cancer would be a good start.
 - Drug assays and costs would be determined on a project-by-project basis. However, the costs should be a fraction of what would be available commercially.
 - This service will focus on funded projects. However, there should be initiatives to support pilot studies, which otherwise could be cost-prohibitive.

2. Catchment Area Priorities (Kinney) (20 minutes)
 - Please see attached presentation.
 - The catchment area's priority cancers were discussed according to incidence and mortality rates.
 - Dr. Kinney's team is also looking at disparities in donating biospecimen samples and genetic testing across race/ethnicity.
 - It was agreed that priority cancers and risk factors for cancer should be included in presentations on the catchment area.
 - While the Research Programs' EAB presentations can include some of the examples in Dr. Kinney's presentation, they can also present other examples.
 - o The CP Program's funding for targeted therapies around some of the priority cancers could be other examples for Dr. Kinney to include in her presentation.
 - o Dr. Zheng will send Dr. Kinney the details.
 - A dashboard is being developed to facilitate finding data on available biospecimens, risk factors, and other topics related to catchment area relevant research.
 - o In the meantime, PIs can contact Rita Musanti and the COE team to obtain needed data.
 - Dr. Kinney was advised that her slide on catchment area relevant research in the Research Programs, which she will present at the upcoming EAB meeting, should present the

examples in the same order as the Research Programs are presenting per the EAB meeting agenda.

3. EAB Updates (Londino-Greenberg)

- The Research Leadership Council advised that the EAB members should be sent the Data Tables from the CCSG RPPR and the Summary Statements from the last CCSG competing renewal application.
- G. Londino-Greenberg also should investigate the possibility of the presenters being able to record their presentations in advance of the EAB meeting.
- There was discussion of whether non peer-reviewed funding that is cancer relevant (e.g., research projects funded by industry, IITs funded by pharmaceutical companies, etc.) should also be presented to the EAB.
 - o Dr. White will investigate whether other cancer centers do so at their EAB meetings.

Next Meeting

Thursday, May 13, 2021 (4:00 pm to 5:00 pm, Zoom)